11/14
08:09 am
rgen
Repligen Co. (NASDAQ: RGEN) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Medium
Report
Repligen Co. (NASDAQ: RGEN) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/14
12:01 am
rgen
Repligen Co. (NASDAQ: RGEN) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Repligen Co. (NASDAQ: RGEN) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/13
06:22 am
rgen
Company News for Nov 13, 2024 [Yahoo! Finance]
Low
Report
Company News for Nov 13, 2024 [Yahoo! Finance]
11/13
02:12 am
rgen
Repligen Corp (RGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
Medium
Report
Repligen Corp (RGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
11/12
03:04 pm
rgen
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View [Yahoo! Finance]
Low
Report
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View [Yahoo! Finance]
11/12
12:12 pm
rgen
Repligen Stock Soars 10% on Record Growth and Bold Moves [Yahoo! Finance]
Low
Report
Repligen Stock Soars 10% on Record Growth and Bold Moves [Yahoo! Finance]
11/12
07:30 am
rgen
Repligen Reports Third Quarter 2024 Financial Results
Low
Report
Repligen Reports Third Quarter 2024 Financial Results
11/5
07:30 am
rgen
Repligen Corporation to Present at Upcoming Investor Conferences
Medium
Report
Repligen Corporation to Present at Upcoming Investor Conferences
10/31
07:30 am
rgen
Repligen to Report Third Quarter 2024 Financial Results
Low
Report
Repligen to Report Third Quarter 2024 Financial Results
10/22
11:53 am
rgen
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release [Yahoo! Finance]
Low
Report
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release [Yahoo! Finance]
10/14
11:28 am
rgen
Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More [Yahoo! Finance]
Low
Report
Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More [Yahoo! Finance]
9/26
11:04 am
rgen
Repligen Co. (NASDAQ: RGEN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $205.00 price target on the stock.
Low
Report
Repligen Co. (NASDAQ: RGEN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $205.00 price target on the stock.
9/24
07:30 am
rgen
Repligen Opens Training & Innovation Center to Elevate Customer Experience
Low
Report
Repligen Opens Training & Innovation Center to Elevate Customer Experience
9/18
04:51 pm
rgen
Repligen financial statements require restatement due to revenue recognition error [Seeking Alpha]
Low
Report
Repligen financial statements require restatement due to revenue recognition error [Seeking Alpha]
9/11
06:49 am
rgen
Several Headwinds Dragged Repligen Corporation (RGEN) in Q2 [Yahoo! Finance]
Low
Report
Several Headwinds Dragged Repligen Corporation (RGEN) in Q2 [Yahoo! Finance]
9/9
05:48 am
rgen
Reasons for the Decline of Repligen (RGEN) in Q2 [Yahoo! Finance]
Low
Report
Reasons for the Decline of Repligen (RGEN) in Q2 [Yahoo! Finance]
9/7
07:45 am
rgen
Repligen Corporation (RGEN) Fell Due to CEO Transition [Yahoo! Finance]
Low
Report
Repligen Corporation (RGEN) Fell Due to CEO Transition [Yahoo! Finance]
8/29
12:52 pm
rgen
Repligen (RGEN) Down 13.1% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
Low
Report
Repligen (RGEN) Down 13.1% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
8/29
08:08 am
rgen
Repligen Corporation (NASDAQ:RGEN) Shares Could Be 23% Below Their Intrinsic Value Estimate [Yahoo! Finance]
Medium
Report
Repligen Corporation (NASDAQ:RGEN) Shares Could Be 23% Below Their Intrinsic Value Estimate [Yahoo! Finance]
8/27
06:30 pm
rgen
Repligen Co. (NASDAQ: RGEN) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $180.00 price target on the stock.
Low
Report
Repligen Co. (NASDAQ: RGEN) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $180.00 price target on the stock.
8/23
08:59 am
rgen
Repligen Corporation (RGEN) Benefitted From Drug Approval [Yahoo! Finance]
Low
Report
Repligen Corporation (RGEN) Benefitted From Drug Approval [Yahoo! Finance]
8/23
07:30 am
rgen
Repligen Corporation to Present at Wells Fargo Healthcare Conference
Low
Report
Repligen Corporation to Present at Wells Fargo Healthcare Conference